Loading clinical trials...
Loading clinical trials...
The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT07439276 · Neurodevelopmental Disorders, Autism Spectrum Disorder, and more
NCT04631042 · Typical Development, Obsessive Compulsive Disorder, and more
NCT06810180 · Attention Deficit Hyperactivity Disorder (ADHD), Sleep, and more
NCT07189442 · Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)
NCT06325813 · Attention Deficit Hyperactivity Disorder
Clinical Study Centers, LLC
Little Rock, Arkansas
Laboratory School
Huntington Beach, California
UC Irvine Child Development Center
Irvine, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions